TIME ON DIALYSIS ADVERSELY AFFECTS RENAL TRANSPLANT OUTCOME IN LUPUS NEPHRITIS

V. Guseva2, O. Inamova3.

College London, London

Methods: Retrospective analysis of all adult SLE patients undergoing renal transplantation over a 40 year period (1975–2015) in two tertiary UK centres followed up until 2017. Cox proportional hazard regression and receiver operator curves (ROC) were used to determine the risk associated with time on dialysis before the transplantation and other potential predictors.

Results: Forty patients (age 35±11 years, 34 female, 15 Caucasian, 15 Afro Caribbean and 10 South Asian underwent transplantation. During a median follow up of 104 months (IQR 80,145), 8 (20%) patients died and the five year survival was 95%. Univariate analysis identified time on dialysis prior to transplantation as the only potentially modifiable risk predictor of survival with a Hazard Ratio of 1.026, p=0.03). ROC curve demonstrated that >24 months on dialysis had an adverse effect with sensitivity of 0.875 and specificity 0.500 for death. No other modifiable predictors were significantly associated with mortality, indicating that time on dialysis had an independent effect.

Conclusions: Increased time on dialysis pre-transplantation is an independent modifiable risk factor of mortality in this cohort of patients with lupus nephritis and should be one of the factors considered for patient selection to transplantation.

Disclosure of Interest: None declared


ANTIBODIES TO PHOSPHATIDYLSERINE-PROTHROMBIN COMPLEX AND ANNEXIN V AS RISK FACTORS FOR THE DEVELOPMENT OF THROMBOTIC COMPLICATIONS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

F. Rebišeteška, I. Belaeva1, V. Mazurov1, S. Lapin2, O. Khanchenko2, V. Guseva, O. Inamova2.

North-Western State Medical University named after I. I. Mechnikov,2 St. Petersburg State Medical University named after I. P. Pavlov, Clinical Rheumatological Hospital No 25, Saint-Petersburg, Russian Federation

Background: Seronegative antiphospholipid syndrome (APS) is a type of APS where the diagnostic levels of “classical” antiphospholipid antibodies (aPL) are not detected, though antibodies to the phosphatidylserine-prothrombin complex (aPS-PT) and annexin V antibodies can be present. The role of these antibodies in the diagnosis of APS needs to be clarified.

Objectives: To study the prevalence of aPS-PT and anti-annexin V antibodies and their role in the development of thrombotic complications.

Methods: 79 SLE patients were enrolled in the study (28-72; mean age 11.0 years, range 2-39). The main group consisted of 38 SLE patients with thrombotic complications and/or obstetric complications (mentioned in the classification criteria for APS), a comparison group consisted of 41 SLE patients without thrombotic obstetric complications. The groups were comparable in age, duration and SLE activity.

ELISA was used to test for aPL: anticardiolipin (aCL) IgG and IgM, anti-β2-glycoprotein-1 antibodies IgGAM (anti-β2GPI) and annexin V antibodies IgG/IgM. Lupus anticoagulant (LA) was evaluated using the DRVV test method.

Results: In 11 patients (29%) of the main group “classical” aPL were not detected, although one SLE patient with thrombosis had elevated levels of antibodies to annexin V IgG (5 U/ml). Sensitivity and specificity of aPL for the diagnosis of APS in patients with SLE were 19% and 96% for anti-PS/PT, 11% and 94% for anti-annexin V antibodies IgG, 11% and 88% for anti-annexin V antibodies IgM respectively.

When comparing two groups using rank test, significant differences were revealed for aCL IgG, anti-β2GPI IgG levels (p<0.05); there were no significant differences between the main group and the comparison group (p>0.05) for levels of aCL IgM, aPS-PT and anti-annexin V antibodies. A positive correlation was revealed between the level of aPS-PT and the following aPL: LA (r=0.45, p=0.00006), aCL IgM and IgG (r=0.4 and r=0.45, p<0.001), anti-annexin V antibodies IgM and IgG (r=0.72 and r=0.47, p<0.001). In a subgroup with elevated aPS-PT levels (>16 U/ml, 6 patients) thrombotic complications were more often than in a subgroup with a normal aPS-PT levels (OR=3.4, p=0.02, OR=4.1, p=0.02, OR=1.5, p=0.01, respectively).

Conclusions: 1. Anti-annexin V antibodies IgG and IgM have high specificity (94% and 88% respectively), but low sensitivity (11% and 11% respectively) for diagnosis of APS in SLE patients.2. A level of aPS-PT has a positive correlation with both “classical” aPL and anti-annexin V antibodies, and has a sensitivity of 19% and a specificity of 96% for the diagnosis of APS in SLE patients. 3. Elevated levels of aPS-PT (>16 U/ml) increase the incidence of thrombotic complications in patients with SLE.

Disclosure of Interest: None declared


TIME DEPENDENT ASSOCIATION OF ACTIVE RENAL DISEASE WITH IRREVERSIBLE ORGAN DAMAGE ACCRUAL IN SYSTEMIC LUPUS ERYTHEMATOSUS


1School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia; 2Chiang Mai University Hospital, Chiang Mai, Thailand; 3Chang Gung Memorial Hospital, Taipei, 4Chang Gung Memorial Hospital, Keelung, Taiwan, Province of China; 5National University Hospital, Singapore, Singapore; 6University of Malaya, Kuala Lumpur, Malaysia; 7University of Santo Tomas Hospital, Manila, Philippines; 8University of Padjadjaran, Bandung, Indonesia; 9Tokyo Women’s Medical University, Tokyo, Japan; 10Tan Tock Seng Hospital, Tan Teng Seng, Singapore; 11Liverpool Hospital, Liverpool, 12Royal Adelaide Hospital and Finders Medical Centre, Adelaide, Australia; 13University of Hong Kong, Pok Fu Lam, Hong Kong; 14St. Vincent’s Hospital, Melbourne, Australia

Background: Lupus nephritis (LN) is an important cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE) often leading to end stage renal failure (ESRF) and necessitating renal transplantation. However, the optimal timing of transplantation in SLE patients with ESRF is uncertain and could potentially affect survival.

Objectives: We investigated time spent on dialysis before renal transplantation and their role in the development of organ damage in SLE patients with ESRF.

Methods: 217 SLE patients were included in the study (MF 7/72; mean age 11.0 years, range 2-39). The main group consisted of 31 SLE patients with thrombotic complications and/or obstetric complications (mentioned in the classification criteria for APS), a comparison group consisted of 186 SLE patients without thrombotic obstetric complications. The groups were comparable in age, duration and SLE activity.

ELISA was used to test for aPL: anticardiolipin (aCL) IgG and IgM, anti-β2-glycoprotein-1 antibodies IgGAM (anti-β2GPI) and annexin V antibodies IgG/IgM. Lupus anticoagulant (LA) was evaluated using the DRVV test method.

Results: In 11 patients (29%) of the main group “classical” aPL were not detected, although one SLE patient with thrombosis had elevated levels of antibodies to annexin V IgG (5 U/ml).

Sensitivity and specificity of aPL for the diagnosis of APS in patients with SLE were 19% and 96% for anti-PS/PT, 11% and 94% for anti-annexin V antibodies IgG, 11% and 88% for anti-annexin V antibodies IgM respectively.

When comparing two groups using rank test, significant differences were revealed for aCL IgG, anti-β2GPI IgG levels (p<0.05); there were no significant differences between the main group and the comparison group (p>0.05) for levels of aCL IgM, aPS-PT and anti-annexin V antibodies. A positive correlation was revealed between the level of aPS-PT and the following aPL: LA (r=0.45, p=0.00006), aCL IgM and IgG (r=0.4 and r=0.45, p<0.001), anti-annexin V antibodies IgM and IgG (r=0.72 and r=0.47, p<0.001). In a subgroup with elevated aPS-PT levels (>16 U/ml, 6 patients) thrombotic complications were more often than in a subgroup with a normal aPS-PT levels (OR=3.4, p=0.02, OR=4.1, p=0.02, OR=1.5, p=0.01, respectively).

Conclusions: 1. Anti-annexin V antibodies IgG and IgM have high specificity (94% and 88% respectively), but low sensitivity (11% and 11% respectively) for diagnosis of APS in SLE patients. 2. A level of aPS-PT has a positive correlation with both “classical” aPL and anti-annexin V antibodies, and has a sensitivity of 19% and a specificity of 96% for the diagnosis of APS in SLE patients. 3. Elevated levels of aPS-PT (>16 U/ml) increase the incidence of thrombotic complications in patients with SLE.

Disclosure of Interest: None declared

Abstract THU0348 – Table 1. Univariate Cox proportional hazard modelling investigating the association of various parameters and mortality showing that only one modifiable risk factor associated with prognosis (time on dialysis, on the longer dialysis the worse the prognosis) and one non-modifiable (rTp taking place after 2000 associated with better survival). SLE: Systemic Lupus Erythematosus, LN: Lupus Nephritis, ESRF: End Stage Renal Failure, rTp: renal transplantation, PD: Peritoneal Dialysis, HD: Haemodialysis, APLS: Antiphospholipid syndrome, MI: Myocardial Infarction, TIA: Transient Ischaemic Attack.

Factor | HR | p-value | 95% CI
--- | --- | --- | ---
Time on Dialysis per month | 0.031 | 1.013 | 1.001–1.026
Gender/male | 0.442 | 0.038 | 0.011–1.613
Ethnicity | 0.987 | 0.995 | 0.537–1.844
Age at SLE diagnosis | 0.552 | 1.021 | 0.953–1.094
Age of LN | 0.941 | 1.003 | 0.920–1.092
Age at rTp | 0.431 | 1.026 | 0.963–1.092
Dialysis PD (vs HD) | 0.764 | 0.706 | 0.673–0.862
Time between LN and Dialysis | 0.540 | 0.789 | 0.513–0.977
LN Duration before Dialysis | 0.553 | 1.021 | 0.953–1.094
Type IV LN | 0.398 | 2.533 | 2.192–1.807
Dialysis Decade | 0.712 | 0.872 | 0.420–2.192
Diabetes Mellitus | 0.561 | 0.038 | 0.001–2319
Hypertension | 0.323 | 0.329 | 0.360–2.987
Dyslipidaemia | 0.905 | 0.872 | 0.92–8.234
APLS | 0.508 | 0.036 | 0.000–672.6
Cardiac disease (MI, stroke, TIA) | 0.673 | 1.071 | 0.463–2.476
Donor source living | 0.353 | 0.459 | 0.089–2.372
Graft Failure post rTp | 0.314 | 2.073 | 0.501–8.567

Conclusions: Active LN is an independent risk factor for damage accrual in SLE. The concomitant independent GC exposure with damage accrual suggests non-GC treatments to reduce active LN are needed to reduce damage burden in SLE.

Disclosure of Interest: None declared


---

Abstract THU0351 – Table 1. Differences in diffusion and perfusion parameters at normal appearing GM and WM level in SLE patients and HCs.

Table 1

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Control</th>
<th>SLE</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>37.2</td>
<td>37.0</td>
<td>0.8</td>
</tr>
<tr>
<td>Sex (M/F)</td>
<td>50/50</td>
<td>40/60</td>
<td>0.05</td>
</tr>
<tr>
<td>Disease duration (years)</td>
<td>10.7</td>
<td>12.8</td>
<td>0.05</td>
</tr>
<tr>
<td>Comorbidities</td>
<td>0.0</td>
<td>0.6</td>
<td>0.01</td>
</tr>
<tr>
<td>CSF C-reactive protein</td>
<td>1.0</td>
<td>1.2</td>
<td>0.01</td>
</tr>
<tr>
<td>CSF IL-6</td>
<td>1.0</td>
<td>1.2</td>
<td>0.01</td>
</tr>
<tr>
<td>CSF IL-17</td>
<td>1.0</td>
<td>1.2</td>
<td>0.01</td>
</tr>
<tr>
<td>CSF TNF-α</td>
<td>1.0</td>
<td>1.2</td>
<td>0.01</td>
</tr>
</tbody>
</table>

Conclusions: Lower ADC values in normal appearing GM and WM in early SLE patients could reflect susceptibility to cerebral ischemia, partially confirmed analyzing perfusion data in NPSLE patients. Further prospective studies with higher sample size are necessary to confirm these findings.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.5702

---

Background: Conventional brain Magnetic Resonance Imaging (cMRI) has a limited usefulness in patients with early diagnosis of Systemic Lupus Erythematosus (SLE), showing not specific abnormalities in up to half of the patients. No data are available about cMRI combined with advanced MRI techniques in early SLE patients.

Objectives: To evaluate differences between early SLE patients, even without overt neuropsychiatric (NP) manifestations, and healthy controls (HCs) in a monocohort, using data derived from cMRI, diffusion-weighted imaging (DWI) and perfusion-imaging (PWI).

Methods: Patients referred to a single tertiary rheumatologic centre with early diagnosis of SLE (less than 24 months), aged less than 55, were consecutively enrolled (01/05/2013–31/12/2017) and imaged with cMRI, DWI and PWI (1.5 Tesla Philips “Signa Achieva” scanner). Data were analysed with a semi-automated measuring system (Diffusion/Perfusion Project Suite, developed in Multiple Sclerosis patients) to co-register apparent diffusion coefficient (ADC), cerebral blood flow (CBF) and volume (CBV), mean transit time (MTT) in normal appearing grey (NAGM) and white matter (NAWM), deep GM (putamen, pallidus, caudate, thalamus) and lesions. Demographic, clinical, serological and treatment information were collected as well as NP events at baseline associated to SLE according to a validated algorithm. Statistical analysis were performed by comparing median (interquartile range, IQR) values for skewed variables between SLE and HCs and with quantile regression adjusted for cardiovascular comorbidities (hypertension, diabetes, previous coronary heart disease, hyperlipidaemia, obesity).

Results: 30 patients with early SLE (mean age 37.0 years, standard deviation SD 10.7, 27 females) and 8 HCs (mean age 40.6, SD 1.2, 6 females) were enrolled. MRI was performed after a mean period of 269 days from diagnosis; mean (SD) Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2k) was 8.87 (3.65) while mean (SD) Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) was 0.40 (0.72); 3 patients were classified as NPSLE at diagnosis. Median (IQR) values of ADC in NAGM and NAWM were 1.15 ± 10-3 mm2/s (1.12–1.16) and 0.86 (0.85–0.88) in SLE, 1.28 (1.16–1.33) and 0.97 (0.87–0.98) in HCs respectively (Table 1). After adjusting for comorbidities, median differences between ADC values remained (p<0.001). SLE patients had lower mean ADC values at bilateral putamen and pallidus. No differences were found in perfusion parameters in all the regions of interest (ROI) and lesions. A trend towards lower CBV and CBF and higher MTT values for NAGM-NAWM in NPSLE compared to non-NPSLE was found.

Disclosure of Interest: None declared

REFERENCES: